IL148713A0 - Oral recombinant lactobacilli vaccines - Google Patents

Oral recombinant lactobacilli vaccines

Info

Publication number
IL148713A0
IL148713A0 IL14871300A IL14871300A IL148713A0 IL 148713 A0 IL148713 A0 IL 148713A0 IL 14871300 A IL14871300 A IL 14871300A IL 14871300 A IL14871300 A IL 14871300A IL 148713 A0 IL148713 A0 IL 148713A0
Authority
IL
Israel
Prior art keywords
vaccines
oral recombinant
recombinant lactobacilli
lactobacilli
oral
Prior art date
Application number
IL14871300A
Other languages
English (en)
Original Assignee
Tno
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tno filed Critical Tno
Publication of IL148713A0 publication Critical patent/IL148713A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • C12N15/746—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora for lactic acid bacteria (Streptococcus; Lactococcus; Lactobacillus; Pediococcus; Enterococcus; Leuconostoc; Propionibacterium; Bifidobacterium; Sporolactobacillus)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL14871300A 1999-09-17 2000-09-18 Oral recombinant lactobacilli vaccines IL148713A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP99203056A EP1084709A1 (en) 1999-09-17 1999-09-17 Oral recombinant lactobacilli vaccines
PCT/GB2000/003575 WO2001021200A1 (en) 1999-09-17 2000-09-18 Oral recombinant lactobacilli vaccines

Publications (1)

Publication Number Publication Date
IL148713A0 true IL148713A0 (en) 2002-09-12

Family

ID=8240652

Family Applications (1)

Application Number Title Priority Date Filing Date
IL14871300A IL148713A0 (en) 1999-09-17 2000-09-18 Oral recombinant lactobacilli vaccines

Country Status (10)

Country Link
EP (2) EP1084709A1 (zh)
JP (1) JP2003509469A (zh)
CN (1) CN1387442A (zh)
AP (1) AP2002002445A0 (zh)
AU (1) AU7433700A (zh)
CA (1) CA2383433A1 (zh)
IL (1) IL148713A0 (zh)
OA (1) OA12023A (zh)
WO (1) WO2001021200A1 (zh)
ZA (1) ZA200201969B (zh)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7220418B1 (en) * 1999-07-05 2007-05-22 Vlaams Interuniversitair Instituut Voor Biotechnologie Delivery of trefoil peptides
US7060687B2 (en) 2001-02-07 2006-06-13 Genmont Biotechnology Co. Live vaccines for allergy treatment
JP4059648B2 (ja) * 2001-08-28 2008-03-12 独立行政法人科学技術振興機構 経口用サイトカイン誘導剤
GB0124580D0 (en) * 2001-10-12 2001-12-05 Univ Reading New composition
EP1319410A1 (en) * 2001-12-11 2003-06-18 Société des Produits Nestlé S.A. Use of micro-organisms for a directed delivery of substances to specific parts of the gut
US20040043003A1 (en) * 2002-01-31 2004-03-04 Wei Chen Clinical grade vectors based on natural microflora for use in delivering therapeutic compositions
CA2492685A1 (en) * 2002-06-18 2003-12-24 Universite Catholique De Louvain Cell wall mutants for delivery of biologically active compounds
WO2004103083A1 (en) * 2003-05-22 2004-12-02 Synbiotics Ab A probiotic composition comprising at least two lactic acid bacterial strains which are able to colonise the gastrointestinal tracts in combination with having intestinal survival property, intestinal binding property, an infection protection property and a fiber fermenting property
WO2005040387A1 (en) * 2003-10-28 2005-05-06 Friesland Brands B.V. Site-specific intestinal delivery and/or production of biologically active substances
EP1768688A4 (en) * 2004-07-02 2009-09-30 Raymond J Dattwyler ORAL BORRELIOSE VACCINE
EP1723965A1 (en) * 2005-05-18 2006-11-22 Stallergenes Sa Compositions for antigen-specific induction of immuno-tolerance via oral immunization
WO2006126682A1 (ja) * 2005-05-27 2006-11-30 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute アルツハイマー病の予防・治療用ワクチン
RU2417092C2 (ru) * 2005-10-06 2011-04-27 Проби Аб Применение lactobacillus для лечения аутоиммунных заболеваний
US8802419B2 (en) 2006-03-02 2014-08-12 University Of Massachusetts Modified pathogens for use as vaccines
JP5791009B2 (ja) * 2008-12-22 2015-10-07 アサヒグループホールディングス株式会社 乳酸菌およびそれらを用いた飲食物又は化粧品
PT2694101T (pt) 2011-04-06 2016-12-19 Université Paris Descartes Composições farmacêutivas para prevenção e/ou tratamento de doença por vih em seres humanos
CN103732248B (zh) * 2011-04-06 2018-08-28 拜欧瓦克西姆有限公司 用于预防和/或治疗人中的hiv疾病的药物组合物
CN102580118B (zh) * 2012-02-24 2014-03-12 重庆大学 志贺样毒素Stx1B口服疫苗的制备方法及其产品
US9452205B2 (en) 2012-09-24 2016-09-27 Montana State University Recombinant Lactococcus lactis expressing Escherichia coli colonization factor antigen I (CFA/I) fimbriae and their methods of use
EP3009149B1 (en) * 2013-06-11 2021-10-20 House Wellness Foods Corporation Carrier for transporting substance to macrophages
CA3095489A1 (en) 2018-03-31 2019-10-03 Pebble Labs Usa Inc. Systems, methods and composition of using rnase iii mutants to produce srna to control host pathogen infection
AU2021380725A1 (en) * 2020-11-10 2023-07-06 Elanco Us Inc. Immunogenic probiotic compositions and methods of use including in vaccination
GB202019767D0 (en) 2020-12-15 2021-01-27 Chain Biotechnology Ltd Compostitions and methods
CN113308396B (zh) * 2021-05-18 2023-03-21 上海市公共卫生临床中心 一种植物乳杆菌及在制备新冠疫苗免疫增强剂中的应用
CN113304254A (zh) * 2021-06-07 2021-08-27 吉林大学 一种微小隐孢子虫Cp15重组侵入型乳酸菌活载体疫苗
CN114561313B (zh) * 2021-08-26 2022-09-13 佛山市孛特碧欧微生物科技有限公司 格氏乳杆菌及其应用
GB202209115D0 (en) 2022-06-21 2022-08-10 Chain Biotechnology Ltd Compositions and methods
DE102022119024A1 (de) * 2022-07-28 2024-02-08 INM - Leibniz-Institut für Neue Materialien gemeinnützige Gesellschaft mit beschränkter Haftung Neuartige genetische Werkzeuge
CN117586935B (zh) * 2023-12-01 2024-05-10 华中农业大学 用于产肠毒素大肠杆菌k99菌毛型的乳酸乳球菌载体口服疫苗及应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL8700890A (nl) * 1987-04-15 1988-11-01 Tno Transformatie van lactobacillus, daarbij bruikbare recombinante plasmiden, getransformeerde lactobacillus species en gebruik daarvan.
GB9718616D0 (en) * 1997-09-02 1997-11-05 Queen Mary & Westfield College Oral vaccine

Also Published As

Publication number Publication date
EP1212083A1 (en) 2002-06-12
EP1084709A9 (en) 2001-05-16
ZA200201969B (en) 2003-08-27
EP1084709A1 (en) 2001-03-21
WO2001021200A1 (en) 2001-03-29
AU7433700A (en) 2001-04-24
CA2383433A1 (en) 2001-03-29
OA12023A (en) 2006-04-19
CN1387442A (zh) 2002-12-25
AP2002002445A0 (en) 2002-03-31
JP2003509469A (ja) 2003-03-11

Similar Documents

Publication Publication Date Title
IL148713A0 (en) Oral recombinant lactobacilli vaccines
HUP0202885A3 (en) Vaccines
IL158107A0 (en) Human papillomaviruses vaccine
IL145044A0 (en) Vaccine
HUS1300072I1 (hu) Vakcina
HK1105581A1 (en) Vaccine composition
GB9910812D0 (en) Vaccine composition
GB9901254D0 (en) Vaccines
GB9915204D0 (en) Vaccine
IL148191A0 (en) Recombinant subunit vaccine
GB9906437D0 (en) Vaccine
GB9913327D0 (en) Vaccine
GB9911823D0 (en) New vaccine formulations
GB9909072D0 (en) Vaccine
GB9904048D0 (en) Vaccines
GB9904280D0 (en) Vaccines
GB9909466D0 (en) Vaccines
GB9904412D0 (en) Vaccine
GB9904408D0 (en) Vaccine
GB9922700D0 (en) Vaccine
GB9919260D0 (en) Vaccine
GB9917144D0 (en) Vaccine
GB9916677D0 (en) Vaccine
GB9915205D0 (en) Vaccine
GB9927336D0 (en) Vaccine